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Short title: Impedance cardiography in PAH. 
Abstract  
Background: Noninvasive methods of measuring cardiac output are highly desirable in 
pulmonary arterial hypertension. We therefore sought to validate impedance cardiography 
(ICG) against thermodilution (TD) and cardiac magnetic resonance (CMR) in the 
measurement of cardiac output in patients under investigation for pulmonary arterial 
hypertension. 
Methods : A prospective, cross-sectional study was performed to compare single-point 
measurements of cardiac output obtained by ICG (COICG) technology (PhysioFlow®) with: 
a) contemporaneous TD measurements (COTD) at rest and steady-state exercise during right 
heart catheterisation and b) CMR measurements (COCMR) at rest obtained within 72 hours.  
Results: Paired COICG and COTD measurements were obtained in 25 subjects at rest and 
16 subjects at exercise. COCMR measurements were obtained in 16 subjects at rest. There 
was unsatisfactory correlation and agreement between COICG and COTD at rest (r=0.42, 
p=0.035; bias: 1.21 L/min, 95% CI: -2.334.75 L/min) and exercise (r=.65, p=.007; bias: 
1.41 L/min; 95% CI: -3.996.81 L/min) and, in the change in COICG and COTD from rest 
to exercise (r=0.53, p=0.033; bias: 0.76 L/min, 95% CI: -3.745.26 L/min). There was also 
a lack of correlation and unsatisfactory agreement between resting COICG and COCMR 
(r=0.38, p=0.1; bias: 1.40 L/min, 95% CI: -2.485.28 L/min). In contrast, there was close 
correlation and agreement between resting COTD and COCMR (r=0.87, p<0.001; bias: -0.16 
L/min, 95% CI: -1.971.65). 
Conclusions : In a representative population of patients under investigation for 
pulmonary arterial hypertension, ICG showed insufficient qualitative and quantitative 
value in the measurement of resting and exercise cardiac output when compared with TD 
and CMR. 
Keywords: cardiac output; thermodilution; cardiac magnetic resonance
Introduction  
Pulmonary arterial hypertension (PAH) is characterised by increased pulmonary 
vascular resistance resulting in progressing right ventricular failure, left ventricular 
underfilling and reduced cardiac output (Galiè et al. , 2015) Cardiac output and cardiac 
index either at baseline or following therapeutic interventions have been identified among 
the most robust indicators of right ventricular function and prognosis in PAH (Humbert et 
al. , 2010; McLaughlin et al. , 2002; D'Alonzo et al. , 1991). Accordingly, normalisation of 
cardiac index has become an important treatment goal endpoint in PAH (Galiè et al. , 2015, 
McLaughlin et al. , 2013;). 
Thermodilution (TD) (Ganz et al. , 1971) remains the reference standard for the 
measurement of cardiac output in PAH; it is reliable, detects directional changes and 
correlates well with the Fick technique in patients with precapillary pulmonary 
hypertension even in the presence of low cardiac output and significant tricuspid 
regurgitation (Hoeper et al. , 1999). More recently, cardiac magnetic resonance (CMR) has 
offered a noninvasive method of assessment of the right ventricular function (Hundley et 
al. , 1995) and has been successfully validated against the Fick method in the measurement 
of cardiac output in PAH (Mauritz et al. , 2008). However, both TD and CMR have certain 
limitations. TD is invasive and subject to technical errors (Nishikawa and Dohi, 1993; 
Stevens et al. , 1985) whereas CMR is restricted by a number of factors including higher 
cost and limited availability, time-consuming analysis, incompatibility with infusion 
pumps and requirement of breath holding which may be difficult for patients (Peacock and 
Vonk Noordegraaf, 2013). 
Impedance cardiography (ICG) relies on the principle that variations in the 
bioimpedance to an alternating current flow during cardiac ejection result in a specific 
waveform from which stroke volume can be calculated (Charloux et al. , 2000). ICG is 
attractive due to its potential for noninvasive measurements of cardiac output at rest and 
activity on a beat-to-beat basis (Bour and Kellett 2008; Tang and Tong, 2009); however, it 
has not been adequately validated in PAH to date. We therefore sought to investigate the 
qualitative and quantitative validity of ICG against TD and CMR in the measurement of 
resting and exercise cardiac output in patients under investigation for PAH. 
Materials and Methods  
Study design 
A prospective, cross-sectional study was performed. All consecutive patients who 
underwent right heart catheterisation for investigation of PAH in the Scottish Pulmonary 
Vascular Unit between December 2014 and November 2015 were eligible. Approval from 
the West of Scotland Research Ethics Committee (14/WS/1075) and written consent were 
obtained. 
Single-point measurements of cardiac output were obtained using ICG (COICG) and 
compared with a) contemporaneous TD measurements (COTD) at rest and steady-state 
exercise during right heart catheterization and b) CMR measurements (COCMR) at rest 
obtained within 72 hours. All measurements were performed in a blinded fashion and all 
COICG and COCMR measurements were performed by single operators (MP and GJ, 
respectively).  
Measurements of COICG and COTD at exercise were obtained in patients who consented 
to exercise in the supine position during right heart catheterization. Subjects either 
performed straight leg raising or cycled on an electronically braked ergometer (Angio 
917900, Lode B.V., Groningen, The Netherlands) secured to the catheterisation table. 
Cycling rate was maintained at 60 revolutions·min-1 and workload kept constant matching 
50% of patient’s maximal oxygen uptake (VO2 max) measured the previous day during an 
upright cycle cardiopulmonary exercise test. In order to reach physiological steady state, 
measurements were obtained during the sixth minute of exercise.  
Right heart catheterisation & Thermodilution 
Diagnostic right heart catheterisation was performed according to current guidelines 
(Galiè et al. , 2015). A balloon-tipped, double-lumen, fluid directed 7 Fr Swan Ganz 
catheter was advanced through an 8F introducer sheath inserted into the right internal 
jugular vein. The positioning of the catheter was confirmed with the presence of pulmonary 
artery pressure waveform from its distal port and fluoroscopic visualisation of its distal tip 
in the pulmonary artery. Cardiac output was measured with the TD technique (Ganz et al.  
, 1971) following the injection of 10 mL sterile, ice-cold isotonic (0.9%) saline through the 
proximal (right atrial) lumen of the Swan–Ganz catheter. The drop in temperature was 
measured at the distal thermistor. The final value used was the average of 3 measurements 
agreeing within 10%. 
Impedance Cardiography 
COICG measurements at rest and exercise were obtained using a commercially available 
technology (PhysioFlow®, Manatec Biomedical, Macheren, France), a detailed description 
of which can be found elsewhere (Charloux et al. , 2000; Richard et al. , 2001). In brief, 
PhysioFlow uses variations in the transthoracic impedance to a high-frequency (75 kHz), 
low-amperage (1.8 mA) alternating current across the thorax during cardiac ejection to 
calculate stroke volume. Its basic equation for calculating stroke volume (Signal-
Morphology-ICG™) has resulted from the introduction of a novel approach to impedance 
cardiography in order to overcome the confounding variables of basal thoracic impedance 
(including thorax morphology, fluid and gas content, blood resistivity and skin thickness) 
and inter-electrode distance. This is achieved by relying only on change in impedance (dZ) 
to establish stroke volume, independent of baseline impedance (Z0) (Charloux et al. , 2000, 
Tan et al. , 2006, Tonelli et al. , 2011). 
In the PhysioFlow algorithm, an initial evaluation of stroke volume index is computed 
at rest during 24 consecutive heart beats (autocalibration procedure) by using the largest 
impedance variation during systole (Zmax - Zmin), the largest rate of variation in the 
impedance signal (contractility index, dZ/dt max), the thoracic fluid inversion time (time 
in ms between the start of the QRS complex and the first nadir after the peak of the ejection 
velocity on the first mathematical derivative; a surrogate of the left ventricular ejection 
time), heart rate, and pulse pressure (systolic minus diastolic arterial pressure). Cardiac 
output (l/min) is then calculated by multiplying the stroke volume index by body surface 
area and heart rate [R-R interval determined on the electrocardiographic (ECG) first 
derivative] (Bour and Kellett 2008, Charloux et al. , 2000, Tonelli et al. , 2011). 
COICG measurements required skin preparation with shaving, scraping and cleaning for 
the application of six transcutaneous electrodes (PhysioFlow PF50) and performed by a 
single investigator (MP) as instructed/trained by the manufacturer. Two emitting electrodes 
were applied at the left base of the neck, above the supraclavicular fossa and two sensing 
electrodes along the xiphoid. In the exercising patients, the two sensing electrodes were 
positioned at the left paravertebral area, at the level of xiphoid. One electrode at the mid-
sternum and one at the left lateral chest wall were used to provide a single 
electrocardiogram lead. Subjects’ sex, age, height, weight and supine systolic and diastolic 
blood pressure were logged in the PhysioFlow software and autocalibration was initiated 
after a period of 5 minutes during which subjects remained still and relaxed on the 
catheterisation table. Signal quality was verified by visualizing the electrocardiographic 
tracing and its first derivative (dECG/dt) and the impedance waveform (ΔΖ) and its first 
derivative (dZ/dt) (Charloux et al. , 2000) and approved by the manufacturer following 
manual review in a blinded fashion. COICG measurements were obtained thereafter in 10-
second intervals throughout right heart catheterisation and downloaded to a purpose-
specific notebook computer (Lenovo, North York, Canada). Manual review of the data and 
artifact detection was performed retrospectively. Data thought to be physiologically 
implausible, i.e. stroke volume for a given subject greater than their mean stroke volume 
±20% (at unchanged heart rate, i.e. variation ≤5 beats/min), were deleted from the series. 
The final value of COICG was the average of all values obtained during TD series. 
Cardiac magnetic resonance 
Phase-contrast CMR was performed on a 1.5T MAGNETOM Avanto MRI scanner 
(Siemens, Munich, Germany) during simultaneous electrocardiogram recording and 
continuous breathing. A velocity-encoded, k-space-segmented, gradient-echo sequence 
was used to generate 30 matched pairs of phase and magnitude images (echo 
time/repetition time/flip angle/slice thickness/temporal resolution/image matrix/field of 
view/in-plane resolution/velocity encoding range: TE 2.18/TR 29.9/30°/5mm/dependent 
on heart rate/256×256/320mm×240mm/1.25mm×1.25mm/0-150cm.sec-1). Retrospective 
electrocardiogram gating was used to ensure complete cardiac cycle coverage. The average 
acquisition time was 2–3 minutes, depending on heart rate. Left ventricular stroke volume 
was measured 2–4 cm above the aortic valve and distal to the coronary arterial ostia 
(Mauritz et al. , 2008). Imaging analysis was performed using the Argus software (Siemens, 
Erlangen, Germany). 
Statistical analysis 
Data are presented as means ± standard deviation (SD). Pearson correlation (r) was 
calculated as measures of raw associations between measurements. P values <0.05 were 
considered significant. The agreement between the three techniques was analysed in a 
pairwise manner using the Bland-Altman analysis (Bland and Altman 1986). All analyses 
were performed using the SPSS statistical software (v. 20, IBM SPSS Statistics, Chicago, 
IL). 
Results 
Patient characteristics 
Twenty-eight patients were studied between November 2014 and December 2015. Due 
to failed PhysioFlow autocalibration in 3 patients, the final analysis included 25 patients 
all of whom had paired COICG and COTD measurements at rest; 16 of those patients also 
had paired measurements of COICG and COTD at exercise (5 patients performed straight leg 
raise and 11 patients cycled) and 16 had measurements of COCMR at rest within 72 hours. 
Clinical and physiological patient characteristics are presented in Tables 1 and 2 and 
measurements of COICG, COTD and COCMR in Table 3. None of the patients had significant 
cardiac shunt. Echocardiographic evidence of tricuspid valve regurgitation was present in 
all patients: 14, trace to mild, 7 mild to moderate, and 3 moderate/severe to severe. Atrial 
fibrillation was present in 4 patients. 
Impedance cardiography versus thermodilution 
Correlation between COICG and COTD was weak at rest (r=0.42, p=0.035) but improved 
at exercise (r=0.65, p=0.007) and when looking at changes from rest to exercise (r=0.53, 
p=0.033). Bland-Altman analysis of the resting measurements showed significant  
overestimation of cardiac output by ICG and wide limits of agreement compared with TD 
(bias: 1.21 L/min, 95% confidence interval (CI): -2.334.75 L/min). Although both ICG 
and TD detected an increase in cardiac output from rest to exercise in all cases, their 
agreement remained poor at exercise (bias: 1.41 L/min, 95% CI: -3.996.81 L/min) and 
changes in cardiac output from rest to exercise (bias: 0.76 L/min, 95% CI: -3.745.26 
L/min) (Figure 1, Table 3). 
Impedance cardiography versus cardiac magnetic resonance 
There was no correlation between COICG and COCMR (p=0.1) and the agreement between 
ICG and CMR was poor (bias: 1.40 L/min, 95% CI: -2.485.28 L/min) (Figure 1, Table 
3). 
Thermodilution versus cardiac magnetic resonance 
There was a strong correlation (r=0.87, p<0.01) and good agreement between COTD and 
COCMR (bias: -0.16 L/min, 95% CI: -1.971.65) (Figure 1, Table 3). 
All the above results remained essentially unchanged when the subset of PAH patients 
(n=14) was examined separately (data not shown). 
Discussion 
This study tested ICG against TD and CMR in the measurement of cardiac output in 
patients under investigation for pulmonary arterial hypertension. Whereas there was a close 
correlation and agreement between TD and CMR, ICG technology showed insufficient 
correlation and significant overestimation of cardiac output with at least twice as wide 
limits of agreement compared with TD and CMR. These findings apply for both rest and 
exercise conditions and the change from rest to exercise and did not change when the subset 
of PAH patients was examined separately. 
A previous validation of the PhysioFlow technology against TD (Tonelli et al. , 2011) 
in 39 patients with suspected or known pulmonary hypertension of various aetiologies, 
showed stronger correlations for resting cardiac output (r=0.94) and considerably smaller 
bias (0.3 L/min) but still wide limits of agreement (-2.2 to 2.8 L/min). Elsewhere, relative 
changes in measurements of cardiac index by PhysioFlow during incremental exercise 
were able to help identify subjects with severe PAH but the incremental value of 
PhysioFlow over peak oxygen uptake was relatively modest and measurements were not 
possible in a quarter of patients (Ferreira et al. , 2012). Nonetheless, change in cardiac 
index measured by PhysioFlow has been associated with six-minute walk distance and 
heart rate recovery in 30 patients with pulmonary hypertension of various aetiologies 
(Tonelli et al. , 2013). 
A different ICG device has shown strong correlation with Fick (r=0.84) and TD (r=0.80) 
in the measurement of resting cardiac output and strong agreement with both methods in 
the measurement of resting cardiac index in 39 subjects with precapillary pulmonary 
hypertension (bias: -0.13 L/min/m2, 95% CI: -1.05 to 0.79 L/min/m2 versus Fick; bias: -
0.23 L/min/m2, 95% CI: -1.49 to 0.63 L/min/m2 versus TD) (Yung et al. , 2004). In another 
study of 65 patients with precapillary pulmonary hypertension, whole-body ICG showed 
good correlation with TD (r=0.715) and Fick (r=0.653) and satisfactory agreement with 
both methods in the measurement of resting cardiac output (bias: 0.50, 95% CI: -1.61 to 
2.61 L/min versus TD; bias: -0.54, 95% CI: -2.57 to 1.49 L/min versus Fick) (Taniguchi et 
al. , 2013). Finally, transthoracic bioreactance cardiography, a similar technology to ICG, 
showed acceptable results versus TD (r=0.60, bias: -0.81, 95% CI: -3.54 - 1.92) and Fick 
(r=0.54, bias: 0.02, 95% CI: -2.41- 2.44) in the measurement of resting cardiac output in 
50 patients with pulmonary hypertension of various aetiologies (Rich et al. ,2013). 
Therefore, previous evidence on the validity and reliability of ICG and similar technologies 
in precapillary pulmonary hypertension remains limited to small, individual studies with 
some encouraging but preliminary results. 
The reasons behind the lack of accuracy of the ICG in the present population are not 
clear. As previously stated, the PhysioFlow algorithm should not be confounded by 
determinants of basal thoracic impedance such as thoracic morphology, fluid and gas 
content, perspiration, blood resistivity, skin and subcutaneous adiposity thickness and 
inter-electrode distance (Charloux et al. , 2000). However, motion artifacts induced by 
exercise and exaggerated ventilatory responses to exercise might have interfered with the 
ICG signal (Warburton et al. , 1999; Edmunds et al. , 1982). Furthermore, measurement of 
stroke volume in the PhysioFlow algorithm requires calculation of the ventricular ejection 
time through measurement of the ‘thoracic flow inversion time’ (Charloux et al. , 2000). 
The latter depends on the pulse pressure and heart rate which are typically pathological in 
PAH patients; this potential source of error can be amplified by dissociation between 
electrical and cardiac mechanical events in the lieu of higher pulmonary vascular pressures 
(Ferreira et al. , 2012). Also, the main pulmonary artery in PAH becomes dilated and 
frequently exceeds the aortic diameter which might have introduced an overestimation of 
the largest impedance variation during systole (Zmax−Zmin) during the autocalibration 
procedure (Ferreira et al. , 2012). Finally, very low cardiac output, significant regurgitant 
volumes, hemodynamically significant cardiac shunts and cardiac arrhythmias may hamper 
ICG tracings (Bour and Kellett 2008) but mean cardiac in the present population was 
preserved and none of the patients had significant cardiac shunt. However, three patients 
had moderate/severe-to-severe tricuspid regurgitation and four had atrial fibrillat ion. 
Whether these factors had collectively accounted for the significant minority of patients 
with invalid ICG signal (3 out of 28 patients, 11 %) is unknown. 
The present study is limited by the small and inhomogeneous population. However, the 
present population is well-representative of patients who undergo investigation for PAH in 
clinical practice. Also, CMR was not contemporaneous to ICG and TD but it was 
performed in a blinded fashion within as little as 72 hours to minimize the possibility of 
significant interval changes in cardiac output; this is supported by the good agreement 
between CMR and TD.  
Conclusion 
In a representative population of patients under investigation for pulmonary arterial 
hypertension, ICG technology showed insufficient correlation and significant 
overestimation of cardiac output with at least twice as wide limits of agreement compared 
with TD and CMR. These findings do not support the quantitative and qualitative validity 
of ICG in the current population. Further research is warranted to allow for the routine use 
of other ICG and similar technologies in the noninvasive assessment of central 
haemodynamics in pulmonary arterial hypertension. 
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Figure Legends 
Figure 1: Bland–Altman plots comparing cardiac output measured by impedance 
cardiography (COICG), thermodilution (COTD) and cardiac magnetic resonance (COCMR): 
a) COICG versus COTD at rest; b) COICG versus COCMR at rest; c) COICG versus COTD at 
exercise; d) change in COICG versus change in COTD from rest to exercise; 3) COTD versus 
COCMR at rest. 
 
 
Table 1: Clinical patient characteristics1. 
Characteristic ICG vs. TD    
at rest (n=25) 
ICG vs. TD vs. CMR 
at rest (n=16) 
ICG vs. TD        
at exercise (n=16) 
Age, y 63.8 ± 11.9 59.6 ± 11.5 62.1 ± 12.3 
Sex (male: female) 13: 12 8:8 8:8 
BMI, kg/m2 28.1 ± 5.5 28.4 ± 5.7 28.1 ± 5.3 
WHO FC, II:III:IV 5: 17: 3 4: 11: 1 4: 12: 0 
6MWD, m 268.3 ± 134.8 285.1 ± 140.2 325.9 ± 124.4 
Diagnosis    
IPAH 7 5 4 
CTD 5 3 4 
PoPH 2 2 1 
PH due to left heart disease 3 1 2 
PH due to lung respiratory 
diseases and ⁄ or hypoxia 
4 2 1 
CTEPH  1 1 1 
No PH 3 2 3 
                                                             
1 Data are presented as means ± SD. ICG: impedance cardiography; TD: thermodilution; 
CMR: cardiac magnetic resonance; BMI: body mass index; WHO FC: World Health 
Organization functional class; 6MWT: six-minute walk distance; IPAH: idiopathic 
pulmonary arterial hypertension; CTD: connective tissue disease associated PAH; PoPH: 
portopulmonary arterial hypertension; PH: pulmonary hypertension; CTEPH: Chronic 
thromboembolic pulmonary hypertension. 
Table 2: Physiological patient characteristics at right heart catheterisation2. 
Characteristic ICG vs. TD        
at rest (n=25) 
ICG vs. TD vs. CMR 
at rest (n=16) 
ICG vs. TD             
at exercise (n=16) 
mean PAP, mm Hg 35.3 ± 12.3 35.2 ± 12.4 Rest: 31.9 ± 10.9 
   Exercise: 52.4 ± 17.6 
PAOP, mm Hg 6.5 ± 5.2 6.8 ± 6.3 Rest: 5.5 ± 3.5 
   Exercise: 11.6 ± 6.7 
CO, L/min 4.7 ± 1.7 4.8 ± 1.9 Rest: 5.2 ± 1.8 
   Exercise: 7.9 ± 3.1 
CI, L/min/m2 2.5 ± 0.9 2.6 ± 1.0 Rest: 2.7 ± 0.9 
   Exercise: 4.2 ± 1.6 
PVR, Wood units 7.4 ± 6.2 7.3 ± 6.9 Rest: 5.7 ± 3.7 
   Exercise: 5.6 ± 4.2 
 
                                                             
2 Data are presented as means ± SD. PAP: pulmonary artery pressure; PAOP: pulmonary 
artery occlusion pressure; CO: cardiac output; CI: cardiac index; PVR: pulmonary 
vascular resistance. 
Table 3: Numerical values, Pearson’s correlation coefficient (r) and Bland–Altman 
analyses for cardiac output3. 
 
 Modality
(n) 
Mean CO, L/min Correlation 
coefficient             
(P value) 
Bias, 
L/min 
Lower and 
Upper Limits, 
L/min 
COICG vs. 
COTD 
Rest (25) 5.93 ± 1.66 vs. 
4.72 ± 1.70 
r=0.42 (0.035) 1.21 -2.33  4.75 
 
COICG vs. 
COCMR 
Rest (16) 6.40 ± 1.78 vs. 
5.01 ± 1.77 
r=0.38 (0.1) 1.40 -2.48  5.28 
COICG vs. 
COTD 
Exercise 
(16) 
9.31 ± 3.44 vs. 
7.91± 3.07 
r=0.65 (0.007) 1.41 -3.99  6.81 
ΔCOICG 
vs. 
ΔCOTD 
Rest to 
exercise 
(16) 
3.51 ± 2.69 vs. 
2.75 ± 1.77 
r=0.53 (0.033) 0.76 -3.74  5.26 
COTD vs. 
COCMR 
Rest (16) 4.85 ± 1.88 vs. 
5.01 ± 1.77 
r=0.87 (<0.001) -0.16 -1.97  1.65 
                                                             
3 Data are presented as means ± standard deviation. CO: cardiac output; COICG: 
impedance cardiography-measured cardiac output; COTD: thermodilution-measured 
cardiac output; COCMR: cardiac magnetic resonance imaging-measured cardiac output; 
ΔCOICG and ΔCOTD: changes in COICG and COTD from rest to exercise. 
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